This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Feig DI, Kang D-H, Johnson RJ . Uric acid and cardiovascular risk. N Engl J Med 2008; 359 (17): 1811–1821.
Edwards NC, Steeds RP, Stewart PM, Ferro CJ, Townend JN . Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. JACC 2009; 54 (6): 505–512.
Schrijver G, Weinberger MH . Hydrochlorothiazide and spironolactone in hypertension. Clin Pharmacol Ther 1979; 25 (1): 33–42.
Falch DK, Schreiner A . The effect of spironolactone on lipid, glucose and uric acid levels in blood during long-term administration to hypertensives. Acta Med Scand 1983; 213 (1): 27–30.
Shibutani Y, Ueo T, Takahashi S, Moriwaki Y, Yamamoto T . Effect of ACTH on renal excretion of purine bases in a patient with isolated ACTH deficiency. Clin Chim Acta 2000; 294 (1-2): 185–192.
Namba M, Kikuchi K, Komura H, Suzuki S, Satoh N, Ohtomo T et al. Study on uric acid metabolism in patients with primary aldosteronism. Nihon Naibunpi Gakkai Zasshi 1992; 68 (1): 51–61.
Anzai N, Endou H . Urate transporters: an evolving field. Semin Nephrol 2011; 31 (5): 400–409.
Anzai N, Miyazaki H, Noshiro R, Khamdang S, Chairoungdua A, Shin HJ et al. The multivalent PDZ domain-containing protein PDZK1 regulates transport activity of renal urate-anion exchanger URAT1 via its C terminus. J Biol Chem 2004; 279 (44): 45942–45950.
Lamprecht G, Hsieh C-J, Lissner S, Nold L, Heil A, Gaco V et al. Intestinal anion exchanger down-regulated in adenoma (DRA) is inhibited by intracellular calcium. J Biol Chem 2009; 284 (284): 19744–19753.
Ruggenenti P, Cravedi P, Remuzzi G . Mechanisms and treatment of CKD. J Am Soc Nephrol 2012; 23 (12): 1917–1928.
Miao Y, Ottenbros SA, Laverman GD, Brenner BM, Cooper ME, Parving HH et al. Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the angiotensin II antagonist losartan trial. Hypertension 2011; 58 (1): 2–7.
Dhaun N, Webb DJ . Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of end points in noninsulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. Hypertension 2012; 59 (1): e1.
Talaat KM, el-Sheikh AR . The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease. Am J Nephrol 2007; 27 (5): 435–440.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Cabrera, S., Edwards, N., Steeds, R. et al. Spironolactone increases serum uric acid levels in patients with chronic kidney disease. J Hum Hypertens 28, 210–211 (2014). https://doi.org/10.1038/jhh.2013.66
Published:
Issue Date:
DOI: https://doi.org/10.1038/jhh.2013.66